Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. - Wikidata - awgldk - TriplyDB

Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.

Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.

http://www.wikidata.org/entity/Q35287580

about

Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy The cell surface mucin podocalyxin regulates collective breast tumor budding.Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer PcMab-47: Novel Antihuman Podocalyxin Monoclonal Antibody for Immunohistochemistry.Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability.Proteome-wide epitope mapping of antibodies using ultra-dense peptide arrays Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study.A comparative study of two PODXL antibodies in 840 colorectal cancer patients.Podocalyxin promotes glioblastoma multiforme cell invasion and proliferation via β-catenin signaling.Podocalyxin is a marker of poor prognosis in colorectal cancer Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma.Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer Podocalyxin as a Prognostic Marker in Gastric Cancer Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma.Prognostic role of podocalyxin-like protein expression in various cancers: A systematic review and meta-analysis.Sialofucosylated podocalyxin is a functional E- and L-selectin ligand expressed by metastatic pancreatic cancer cells.Distinct kinetic and mechanical properties govern mucin 16- and podocalyxin-mediated tumor cell adhesion to E- and L-selectin in shear flow.Gender, anthropometric factors and risk of colorectal cancer with particular reference to tumour location and TNM stage: a cohort study Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer.Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.Podocalyxin-like protein expression in primary colorectal cancer and synchronous lymph node metastases.Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study.Influence of anthropometric factors on tumour biological characteristics of colorectal cancer in men and women: a cohort study Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome Podocalyxin influences malignant potential by controlling epithelial-mesenchymal transition in lung adenocarcinoma.Multimodal treatment strategies for locally advanced rectal cancer.Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1.Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker.Did the reporting of prognostic studies of tumour markers improve since the introduction of REMARK guideline? A comparison of reporting in published articles.In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion.Podocalyxin regulates astrocytoma cell invasion and survival against temozolomide Environmental factors and risk of aggressive prostate cancer among a population of New Zealand men - a genotypic approach.Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer.Role of podocalyxin in astrocytoma: Clinicopathological and in vitro evidence Colorimetric protein sensing using catalytically amplified sensor arrays.

P2860

Q21146638-32619313-A0B1-425A-9961-F269ABD4BF2D Q27338644-EA3570A4-BA7C-484B-89F1-E20EB1D53AFD Q27496689-0F900DE1-7F31-4944-997B-2213212D2CDA Q33600992-017085ED-C26E-4AD0-9131-6187523F7DE8 Q33696650-9D088ECD-3B73-42FE-96B4-C4484ECCEFFF Q33718734-C184BBE4-31BD-4D15-9489-6D55E9EB69AA Q33740175-2332E415-7B5D-48E3-8E14-5F541DED58A0 Q33938468-F71DFD1B-0A29-4C6A-B978-C6521B4E4AF1 Q34414641-226E117A-CC13-466D-9710-F41C2E066A24 Q34485223-5DDDBD14-265B-43E4-BD1E-E0CEB0965CFB Q35022551-10AEE6CD-1EB6-4ED9-A029-F48A3842C708 Q35647464-03ABEBC2-0906-4CD7-B18C-2B7A6AE08FD8 Q35656610-21CDAEE3-B059-4019-A45E-00458EDB4AD7 Q35835106-7849BE7E-ED1F-4900-9730-788044F08051 Q35870705-00FBCE2B-AAC0-4156-A8C8-72E2A1DA7043 Q36091414-A04AFF53-6312-4019-A287-837FB5FE0104 Q36236781-115C95B5-4B85-4AE6-8669-56BDF632637D Q36308972-1C0B9A52-853C-44EB-8B9C-E2E684F49600 Q36413037-55909E91-50AD-4470-9DA2-2372EB73F538 Q36418348-9663A398-CE9B-441C-B113-911DED4EC776 Q36468662-CCB2D16F-0437-4BAC-B884-4D867CC48D85 Q36689001-F1C23F52-A644-45A5-8DA5-6A31D62870BE Q36886612-09DB1088-423A-4876-B844-1A2E4A0212FF Q36924797-1490F83F-4B43-49C6-BB13-0939B53C50EA Q37114865-2C1887F9-5562-458D-B1F0-FFAED17B92C2 Q37355802-19DDC63F-5A55-487D-A21C-E3430773F119 Q37418190-E4FE0B4F-0D29-4377-97C5-6F2AD454696E Q37697790-FFF75B29-2DD5-48CD-BA4D-8AD0C0371126 Q37724074-BB54AFAE-5A80-4678-A400-A5DCF5D51CD5 Q37735632-89BE6910-EE68-4872-923D-1B084943111D Q38002470-717C3AC2-1FCE-4028-8B78-DEB2571A138B Q38259585-6AC327B2-CF78-429C-825E-76066F87CB8E Q38645392-1FA7A95F-3BF6-46CA-A3BE-503A73304B86 Q38671095-7DEA4162-516F-4880-A95E-E1946722D347 Q39188239-F2E3637E-7B37-43F4-BC60-BF3992CC8430 Q39873210-4F16FBE4-AE4C-4ED2-AC23-DA4EB79DB321 Q40311743-7ABE18F0-73B7-4A7E-9A53-6D003AEB2558 Q40802902-4E7083C5-CEA7-4572-8F32-CF884E96714A Q41790462-1BE0EC78-B024-4467-9926-20E8C768C89D Q42388319-B6FC8ADD-9CAF-4A5E-ACA8-EE0D75FBB068

P2860

Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.

http://www.wikidata.org/entity/Q35287580

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Overexpression of podocalyxin- ...... rognosis in colorectal cancer.

@ast

Overexpression of podocalyxin- ...... rognosis in colorectal cancer.

@en

type

label

Overexpression of podocalyxin- ...... rognosis in colorectal cancer.

@ast

Overexpression of podocalyxin- ...... rognosis in colorectal cancer.

@en

prefLabel

Overexpression of podocalyxin- ...... rognosis in colorectal cancer.

@ast

Overexpression of podocalyxin- ...... rognosis in colorectal cancer.

@en

P1433

Q35287580-9FE94C9A-F6CC-4FB4-AB5D-48E41ADB9E9B

P1476

Q35287580-8D0A9537-1E9B-4727-9233-28C864DFE29B

P2093

Q35287580-446038A6-7033-4702-AEF7-0ACBC046E7F7

Q35287580-49B26AF4-A863-490F-A1DD-DAEECA224A22

Q35287580-67BBE18C-0D7B-486B-82D9-D33E6BFF19EA

Q35287580-704DC09B-E397-4F39-A8D0-3B8F8CD36A84

Q35287580-722F58BA-2187-44C2-A9FF-6E0300F3EC90

Q35287580-727EC2F4-A33D-4C90-B010-070C1F5FEB17

Q35287580-8F7996A7-AC30-4704-A83A-081B853ABEEB

Q35287580-D932688B-7D2C-4110-8A17-EA025DE17AAD

Q35287580-DE7B58A0-DA54-4505-8EB9-FD6B5096E2F5

P2860

Q35287580-0C7B3DAB-4618-4E39-9365-3959BF4064C0

Q35287580-1A9F6145-6E3A-40F1-AA8A-559DB00D27CC

Q35287580-22A8C604-FCED-45A9-B9C9-FAC9F10EE8A0

Q35287580-3C5BFF2A-8841-4CDD-AA3B-5C8E50AA18FC

Q35287580-4302E1F3-639D-4A4D-B113-B2B6564F992A

Q35287580-47D44336-8C59-4B91-8061-BC03F2350285

Q35287580-4C4FE542-7E6C-468A-A969-336AF49C7AE0

Q35287580-579041A7-8F74-4143-868E-D13983E32100

Q35287580-595B669F-FA01-43C4-B087-1BD2AA1BB228

Q35287580-5AB3EAD9-E059-4F4F-9E82-B4A22A96EE3E

P2888

Q35287580-30061766-B6E4-409A-B617-529A4F58984E

P304

Q35287580-0B82DB70-89B1-4C1A-A00F-E0C871C65C2A

P31

Q35287580-8C1F713C-1F1D-40E3-9DE6-E8588EF4E71C

P356

Q35287580-06AA1C28-2048-4DBF-9B46-D5F96160FAE7

P407

Q35287580-9778A9EF-4D1D-49CD-9B79-A3E72D4D4FF9

P433

Q35287580-E548FCA1-83BB-49A7-95C0-0B2740278540

P478

Q35287580-7EC2DC08-91C6-4B86-8EA0-AD063CBD46AC

P50

Q35287580-3F875D82-F9DA-44FA-8958-AD70A00CE710

Q35287580-6FD51204-6F7C-4F7C-BAD2-8DB08A51A981

Q35287580-DF823478-C7DB-4BED-B3AA-8DD70F940B03

P577

Q35287580-B3B641DE-966D-453A-A0DC-36E7160677AC

P5875

Q35287580-E97E7B67-D3E0-4536-8FAD-E06E1A7E21C1

P698

Q35287580-558DF0BA-1888-4039-A424-9C4C640C88FD

P921

Q35287580-304D5323-4BC6-42B6-9AAC-8741C4E1195C

Q35287580-DC78CA1B-3517-4F2A-8137-E896D3CF0E57

P932

Q35287580-F7D27B3C-C4C0-4819-8C23-2E6C82379ACC

P356

P1433

British Journal of Cancer

P1476

Overexpression of podocalyxin- ...... prognosis in colorectal cancer

@en

P2093

A Gaber

http://www.w3.org/2001/XMLSchema#string

A Johnsson

http://www.w3.org/2001/XMLSchema#string

A Larsson

http://www.w3.org/2001/XMLSchema#string

B Nodin

http://www.w3.org/2001/XMLSchema#string

J Eberhard

http://www.w3.org/2001/XMLSchema#string

K Jirström

http://www.w3.org/2001/XMLSchema#string

M E Johansson

http://www.w3.org/2001/XMLSchema#string

P Kucharzewska

http://www.w3.org/2001/XMLSchema#string

S Wangefjord

http://www.w3.org/2001/XMLSchema#string

P2860

The CD34-related molecule podocalyxin is a potent inducer of microvillus formation

Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7

The epithelial-mesenchymal transition generates cells with properties of stem cells

Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin

Global cancer statistics, 2002

Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin

Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression

Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis

Podocalyxin variants and risk of prostate cancer and tumor aggressiveness

Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells

P2888

P304

666-672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2011.295

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Charlotte Welinder

Mattias Belting

P577

2011-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51559509

http://www.w3.org/2001/XMLSchema#string

P698

21829192

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3188928

http://www.w3.org/2001/XMLSchema#string